Background: Preclinical data demonstrate a key role for the epidermal growth factor receptor (EGFR) in the carcinogenesis of cutaneous squamous cell carcinomas (CSCCs). There are, however, limited data on the efficacy of EGFR inhibitors in incurable, recurrent, and/or metastatic CSCC.
T reatment options for advanced or recurrent cutaneous squamous cell carcinoma (CSCC) are limited, and patients in whom surgery, radiation, and/or chemotherapy have failed have a poor prognosis.
The epidermal growth factor receptor (EGFR) plays a major role in ultraviolet lighteinduced skin tumorigenesis. 1 Ultraviolet light irradiation activates EGFR in cultured keratinocytes and skin, leading to keratinocyte proliferation, suppression of apoptosis, and epidermal hyperplasia. 2 In animal models of skin carcinogenesis, EGFR and its ligand transforming growth factor-a have been shown to be critical mediators of keratinocyte proliferation and skin tumor growth, 3 in part through stimulation of the downstream effectors Akt and signal transducer and activator of transcription 3. 4, 5 EGFR is overexpressed in 35% to 100% of CSCCs [6] [7] [8] and is associated with increased risk for disease progression. 8 In animal genetic models 9 and xenograft models, 10 the EGFR tyrosine kinase inhibitors AG1478 and AEE788 induced keratinocyte apoptosis, 9,10 delayed onset of epidermal hyperplasia, and reduced tumor growth.
There have been limited studies of EGFR inhibitors in CSCC.
11 -13 Herein we report the results of a phase II clinical trial with the EGFR tyrosine kinase inhibitor gefitinib in patients with incurable recurrent and/or metastatic CSCC.
PATIENTS AND METHODS
This single-arm, phase II study was conducted at The University of Texas M.D. Anderson Cancer Center. The study was approved by the Institutional Review Board and was conducted in accordance with the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines.
Eligible patients had locoregionally recurrent and/or metastatic CSCC not amenable to curative therapy including surgery or radiation, an Eastern Cooperative Oncology Group performance status of 0 to 2, no more than 1 prior chemotherapy regimen, and no prior EGFR inhibitors.
Patients received gefitinib, 250 mg orally daily, until disease progression or unacceptable toxicity. Assesment of response was performed every 2 cycles (each cycle lasting 28 days).
The primary end point was to determine the objective response rate (ORR) assessed according to the World Health Organization criteria.
14 Secondary objectives included determining the duration of response, overall survival, and adverse events (assessed using the National Cancer Institute Common Toxicity Criteria, version 2.0).
A 2-stage phase II design was used with a power of 90% and a type I error rate of 5%. The target ORR of interest for gefitinib was assumed to be 20%, and the lower activity level was taken to be 5%. The treatment would be accepted as effective if the ORR was at least 5 of 39 and rejected otherwise.
RESULTS
A total of 40 patients were enrolled (Table I ). The median time of receiving treatment was 3.4 months (range, 0.9-33.5). The gefitinib toxicity profile was favorable (a median of 2 adverse events per patient, with most being grade 1-2), as summarized in Supplemental (Table II ). An additional 13 patients (35%) had stable disease at 8 weeks (95% CI, 0.20-0.53). The median duration of response was 31.4 months (95% CI, 3.91-not applicable). ORR was higher in patients with locally advanced (defined as unresectable disease in patients without distant metastases) or locoregionally recurrent disease (6 of 29 evaluable patients) than in patients with metastatic disease (0/8 evaluable patients).
Median overall survival was 12.9 months (95% CI, 8.5-25.0). Median progression-free survival was 3.8 months (95% CI, 2.2-5.7) (Supplemental Fig 1; available at http://www.jaad.org).
DISCUSSION
In this phase II study for incurable CSCC, gefitinib was associated with an ORR of 16% and a disease control rate of 51%. Treatment was well tolerated. The ORR of 16% did not meet the rate of 20% targeted in the study design.
Investigation of systemic treatment for advanced or recurrent CSCC has been limited, with few prospective trials. Maubec et al reported results of the first prospective evaluation of cetuximab, a monoclonal antibody to EGFR, in 36 chemotherapy-naive patients with unresectable CSCC 13 and showed an ORR of 28% and a disease control rate of 69% at 6 weeks. Notably, only 3 of 36 patients had metastatic disease and 15 of 36 patients had no prior therapy.
Although we observed lower response and disease control rates with gefitinib than in the trial by Maubec Although gefitinib had only modest activity in incurable CSCC, the adverse event profile was favorable.
account of significant differences in the patient populations. Our population included a higher percentage of patients with recurrence following surgery and/or radiation (88% and 83%, respectively), and 22% of patients had distant metastasis. Prior chemotherapy had been given to 45% of patients. Given these characteristics, the activity of gefitinib observed is of interest. We have also studied gefitinib in patients with aggressive or recurrent CSCC who were candidates for either resection or definitive radiation. 15 In the neoadjuvant setting, the ORR to gefitinib was 45% (10 of 22), with 3 of 4 complete responses confirmed pathologically. Taken together, these results suggest that gefitinib has at least modest activity.
Patients with aggressive CSCC in routine clinical practice often present at an advanced age and frequently have additional comorbidities that lead to immunosuppression, rendering them suboptimal candidates for cytotoxic therapy. The activity of EGFR single agents in this setting is therefore relevant, especially if disease control rates in the range of 50% can be achieved with a favorable adverse event profile.
Efforts to characterize the molecular landscape of CSCC have recently been completed, which could assist in development of novel drugs and/or identification of biomarkers of response to therapy. These studies highlight a high mutational load as a key characteristic of CSCC. [16] [17] [18] Unfortunately, many of these mutations occur in tumor suppressor genes, for which therapeutic interventions are challenging. Notably, epidermal growth factor receptor gene (EGFR) activating mutations were infrequently seen in these reports and in others, [19] [20] [21] and they are therefore unlikely to explain the ORR associated with gefitinib in our study. In our previous trial of neoadjuvant gefitinib in CSCC, we did not identify any associations between EGFR mutations, gene copy number gains, or protein expression/phosphorylation and outcomes. 15 In conclusion, this phase II trial demonstrated modest activity of gefitinib in metastatic or locoregionally recurrent CSCC. These results support a potential therapeutic role of EGFR tyrosine kinase inhibitors in this disease, for which there are no approved drugs. Further studies are needed, however, to identify patients who are more likely to respond to these agents and determine how to best integrate them into the treatment strategy in both curative-intent and palliative settings. 
